Statin-intolerant patients need a different type of clinical trial

November 18, 2011 By Joseph Bonner

(Medical Xpress) -- Millions of people take statins, the blockbuster drug that lowers low-density lipoprotein (LDL), the so-called bad cholesterol. But as many as 20 percent of them develop adverse effects such as muscle fatigue and weakness and impaired cognition. Rockefeller University scientists Patricia Maningat and Jan L. Breslow, writing in this week’s issue of the New England Journal of Medicine, argue that clinical trials need to be designed to address the needs of statin-intolerant patients.

“Statins are so widely used that side effects can translate into substantial public health problems,” says Breslow, Frederick Henry Leonhardt Professor and head of the Laboratory of Biochemical Genetics and Metabolism. “It’s imperative that we design special , such as pragmatic trials, to determine the best treatment options for patients who have adverse effects from statins.”

Statins, first introduced in 1987, work by blocking an enzyme called HMG-CoA reductase, which plays a key role in the liver’s production of . Randomized clinical trials have shown that side effects occur in less than 5 percent of patients who take statins, although as many as 20 percent are reported to experience side effects in clinical practice. Maningat and Breslow attribute this discrepancy to how patients are selected for clinical trials, which typically under enroll two groups likely to experience statin-related side effects — older patients and women — as well as patients who drink large amounts of alcohol, take several other medications, or have complicated medical conditions. The problem, the researchers say, is that these groups are likely to be prescribed statins in the real world.

According to the researchers, the most common side effect of statin use, a muscular condition known as statin-associated myopathy, lacks a standard definition, which also leads to the discrepancy of reported . For example, high levels of an enzyme called creatine phosphokinase typically indicate statin-associated myopathy, but this condition is not necessarily accompanied by elevated levels of this enzyme. Finally, cognitive impairment, the most common neurologic problem associated with statin use, is generally not measured in the clinic or it’s disregarded as a consequence of aging.

Maningat and Breslow argue that introduction of new drugs for people who can’t tolerate statins lags because most non-statin therapies are tested in clinical trials as additive therapies on top of statins. For example, in a recent trial on the benefits of combining niacin with statins, called the AIM-HIGH trial, 94 percent of those enrolled were taking a statin drug at the time they were enrolled. In this study, niacin combined with a statin was found to have no cardiovascular benefits and a trend towards increased risk of ischemic strokes.

“In the AIM-HIGH trial, niacin was not found to be useful when combined with a statin, and indeed, it might be harmful,” says Breslow. “Fortunately, we do know that niacin alone can be beneficial. However, if a new drug was tested with a statin and the same result was found, it would be impossible to determine if it had standalone benefits and its value would be lost for statin-intolerant patients.”

Since statins have been shown to reduce the risk of cardiovascular disease and have become standard of care, placebos are considered by some experts to be unacceptable when studying the effectiveness of new cholesterol modifying drugs, and therefore most studies employ the study drug as an add-on to statin therapy. That severely complicates the conduct of meaningful trials for statin-intolerant patients. But Maningat and Breslow say that pragmatic trials, which occur in the context of usual care and recruit patients from broad a variety of practice settings, may be well suited for determining the best treatment options for patients who experience side effects from statins. In pragmatic trials, patients and doctors usually aren’t blinded to the treatment and have the option to adjust or discontinue the treatment.

“Although less rigidly controlled than randomized trials, pragmatic trials are conducted in real-world settings and provide valuable information and guidance for clinical practice,” Breslow says. “Given the complexity of statin intolerance, physicians need a simple way to identify patients who experience .” Maningat and Breslow suggest that patients who find their quality of life diminished to the point where they discontinue or change their statin regimen be defined as statin intolerant.

Enrolling patients in pragmatic trials, the researchers say, would involve, among other things, simplifying the definition of statin intolerance and screening patients to determine their perception of their symptoms, quantify the effects of statin intolerance on their daily activities and monitor changes in quality of life.

“We’re not suggesting that pragmatic clinical trials for statin-intolerant would be easy or inexpensive, but this population’s needs are not being met,” says Maningat, who is a research associate in Breslow’s lab. “It’s time to begin a dialogue on the best way to meet them.”

Explore further: Study finds no link between statins and cancer risk

More information: The New England Journal of Medicine online: November 15, 2011, Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients, Patricia Maningat and Jan L. Breslow

Related Stories

Study finds no link between statins and cancer risk

July 25, 2011
(Medical Xpress) -- A new study published in the Journal of the American College of Cardiology reports that, contrary to previous studies, the use of cholesterol reducing statin drugs does not increase the risk of patients ...

A new use for statins?

October 18, 2011
Older patients who happened to have been taking cholesterol-lowering statin drugs when admitted to the hospital with serious head injuries were 76 percent more likely to survive than those not taking the drugs, according ...

Research shows earlier statin treatment can be cost-effective

August 16, 2011
The advent of low-cost, generic forms of cholesterol-lowering drugs has shifted the equation in managing lower-risk patients with elevated cholesterol levels, according to a multicenter study led by researchers at UCSF.

Recommended for you

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

Engineered liver tissue expands after transplant

July 19, 2017
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.

Lunatic Fringe gene plays key role in the renewable brain

July 19, 2017
The discovery that the brain can generate new cells - about 700 new neurons each day - has triggered investigations to uncover how this process is regulated. Researchers at Baylor College of Medicine and Jan and Dan Duncan ...

New animal models for hepatitis C could pave the way for a vaccine

July 19, 2017
They say that an ounce of prevention is worth a pound of cure. In the case of hepatitis C—a disease that affects nearly 71 million people worldwide, causing cirrhosis and liver cancer if left untreated—it might be worth ...

Omega-3 fatty acids fight inflammation via cannabinoids

July 18, 2017
Chemical compounds called cannabinoids are found in marijuana and also are produced naturally in the body from omega-3 fatty acids. A well-known cannabinoid in marijuana, tetrahydrocannabinol, is responsible for some of its ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

jerryd
not rated yet Nov 18, 2011

I have news for you Lipitor told Doc's bad side effects are rare, under 1%. But of course they were lying.

Let's take my experience. Over 3 months I took lipitor I got much weaker with increased muscle pain not even moving so bad I was bed ridden. I told my Doc and she said keep taking it for my heart but I told her no way. I stopped and in 3 weeks I was much better. I also got another Doc. Sadly I switched to Zocor and after several months got extremely depressed. Again stopping I was well in 3 weeks. No problem with either since stopping 10 yrs ago.

I also took care of my eldely mother who had fibromyalgia but I'd bet as I took after her, that her FM was caused by Lipitor too and maybe killed her.

I should mention a very low fat, high fiber, low calorie but high volume diet has cut my Col, etc by 50% back into the healthy range.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.